Novo Is Open to Acquisitions. Here Are 2 Companies That Would Be Great Candidates to Buy

Key Points Novo Nordisk could strengthen its obesity pipeline by buying out Kailera Therapeutics and Viking Therapeutics. These two biotechs boast highly promising mid and late-stage programs. Even without acquisitions, Novo could have a significantly improved approved portfolio within a few years. 10 stocks we like better than Novo Nordisk › Novo Nordisk (NYSE: NVO) has a problem. The company generates most of its revenue from its diabetes and obesity products, but stiff competition from Eli Lilly (NYSE: LLY) in these markets has significantly disrupted its business. To make matters worse, other drugmakers will launch brand-new products in this field over the next few years. Novo Nordisk could struggle even more in a more competitive environment.